Business Description
Avalyn Pharma Inc
NAICS : 541714
SIC : 2834
ISIN : US05348Y1055
Description
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20.6 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.31 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -13.05 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.65 | |||||
9-Day RSI | 38.35 | |||||
14-Day RSI | 43.82 | |||||
3-1 Month Momentum % | 30.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 33.12 | |||||
Quick Ratio | 33.12 | |||||
Cash Ratio | 32.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -23.58 | |||||
ROIC % | -198.37 | |||||
ROC (Joel Greenblatt) % | -1992.83 | |||||
ROCE % | -24.7 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.72 | |||||
Price-to-Tangible-Book | 3.72 | |||||
EV-to-EBIT | -20.57 | |||||
EV-to-EBITDA | -20.63 | |||||
EV-to-FCF | -20.16 | |||||
| Price-to-Net-Current-Asset-Value | 4.48 | |||||
| Price-to-Net-Cash | 4.55 | |||||
Earnings Yield (Greenblatt) % | -4.86 | |||||
FCF Yield % | -3.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVLN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avalyn Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.259 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 43.82 | ||
| 14-Day ATR ($) | 2.273033 | ||
| 20-Day SMA ($) | 35.8655 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 24.15 - 40.17 | ||
| Shares Outstanding (Mil) | 44.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avalyn Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avalyn Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Avalyn Pharma Inc Frequently Asked Questions
What is Avalyn Pharma Inc(AVLN)'s stock price today?
The current price of AVLN is $33.40. The 52 week high of AVLN is $40.17 and 52 week low is $24.15.
When is next earnings date of Avalyn Pharma Inc(AVLN)?
The next earnings date of Avalyn Pharma Inc(AVLN) is .
Does Avalyn Pharma Inc(AVLN) pay dividends? If so, how much?
Avalyn Pharma Inc(AVLN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers